Physician profile
Tahera Ali
NPI 1316104466
$5,200.26
in general payments reported to CMS, 2019-2025
32 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $1,081 · 2021: $525 · 2022: $489 · 2023: $364 · 2024: $936 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,390.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $852.54 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $437.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $375.42 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $305.77 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $277.43 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $263.66 | 2020-2025 | |
| Amarin Pharma, INC. | $228.72 | 2019-2021 | |
| Abbott Laboratories | $152.47 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $126.15 | 2024-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $116.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.10 | 2019-2022 | |
| Horizon Therapeutics Plc | $67.99 | 2021-2022 | |
| Astellas Pharma US INC | $56.69 | 2023-2025 | Veozah |
| Dynavax Technologies Corporation | $56.33 | 2019-2023 | Heplisav-B |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.85 | 2022 | |
| Shield Therapeutics INC | $43.09 | 2022 | |
| Daiichi Sankyo INC. | $40.97 | 2021 | |
| Genentech USA, INC. | $37.38 | 2020-2021 | |
| Dexcom, INC. | $34.62 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $29.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.63 | 2019-2022 | |
| Mannkind Corporation | $27.02 | 2021-2022 | |
| Corcept Therapeutics | $20.35 | 2025 | Korlym |
| Abbvie INC. | $19.72 | 2023 | Ubrelvy |
| Cagent Vascular INC | $19.00 | 2025 | Serrantor |
| Xeris Pharmaceuticals, INC. | $15.60 | 2023 | Gvoke Hypopen |
| Valeritas, INC. | $15.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.28 | 2020 | |
| Esperion Therapeutics, INC. | $12.27 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.89 | 2019 | |
| Avion Pharmaceuticals | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tahera Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.